|
The impact of sleep disturbances (SD) on quality of life, psychological morbidity, and survival of advanced cancer patients (ACP) and caregivers (CG). |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - FACIT.org |
Consulting or Advisory Role - Abbvie; Bayer; GlaxoSmithKline; Pfizer |
Research Funding - Bayer (Inst); Genentech (Inst); Ipsen (Inst); Novartis (Inst); Pfizer (Inst) |
Travel, Accommodations, Expenses - Bayer; GlaxoSmithKline |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Biscayne Pharmaceuticals; PrescriptIQ; Venaxis |
Consulting or Advisory Role - AbbVie; Amgen; Biomarin; Biscayne Pharmaceuticals; Circle Pharma; Cyclacel; Drais Pharmaceuticals; Genentech/Roche; Portola Pharmaceuticals; Shionogi; Venaxis |
Research Funding - Dicerna (Inst); OncoTherapy Science (Inst) |
Patents, Royalties, Other Intellectual Property - pending patent related to a genomic prescribing system; pending patent related to a genomic prescribing system (Inst); royalties related to UGT1A1 genotyping for irinotecan; royalties related to UGT1A1 genotyping for irinotecan (Inst) |
Expert Testimony - multiple generic companies |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |